NCT05735327Active, not recruiting
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
Effectiveness and Safety of Brigatinib Treatment as First-line Therapy Administered to ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients. Prospective, Multicenter, Observational Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib. Another aim is to learn about the overall rate of participants who respond to the treatment with brigatinib. Participants will receive brigatinib as part of their normal clinical practice. Data will be collected during regular visits to the hospital (a total of up to 12 visits is planned throughout study duration).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 10 Feb 2023
- Start date
- 22 May 2023
- Primary completion date
- 26 Apr 2027
- Lead sponsor
- Takeda
- Diseases
- Lung cancer
- NCT number
- NCT05735327
What you commit to
- Study type: Observational
- Planned participants: 50
- From 22 May 2023 to the primary completion date, 26 Apr 2027
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or planned participation in an interventional clinical trial for ALK positive non-small cell lung cancer (NSCLC).
Other
- Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Who the study is looking for
- Adult (aged ≥18) ALK positive NSCLC participants receiving brigatinib as a first-line treatment in the scope of NDP.
- Participants willing to participate in the study and signed ICF.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy Coordinator of this site? Confirm its status | Bydgoszcz | Poland | Unknown status |
| Centrum Pulmonologii i Torakochirurgii w Bystrej Coordinator of this site? Confirm its status | Bystra | Poland | Unknown status |
| Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie Coordinator of this site? Confirm its status | Krakow | Poland | Unknown status |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie- Panstwowy Instytut Badawczy Oddzial w Krakowie Coordinator of this site? Confirm its status | Krakow | Poland | Unknown status |
| SPZOZ Uniwersytecki Szpital Kliniczny nr 2 im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Lodzi Centralny Szpital Weteranow Coordinator of this site? Confirm its status | Lodz | Poland | Unknown status |
| Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie Coordinator of this site? Confirm its status | Lublin | Poland | Unknown status |
| Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu Coordinator of this site? Confirm its status | Poznan | Poland | Unknown status |
| Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu. Coordinator of this site? Confirm its status | Poznan | Poland | Unknown status |
| Podkarpackie Centrum Chorob Pluc Coordinator of this site? Confirm its status | Rzeszów | Poland | Unknown status |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Coordinator of this site? Confirm its status | Warsaw | Poland | Unknown status |
| Instytut Gruzlicy I Chorob Pluc Coordinator of this site? Confirm its status | Warsaw | Poland | Unknown status |
| Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii Coordinator of this site? Confirm its status | Wroclaw | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.